Supplementary material
Supplementary materialTable S1 Search Strategy for Humanistic Review Conducted for Embase? and MEDLINE? Using Embase? PlatformNo.Query#1'chronic obstructive lung disease'/syn OR 'chronic obstructive lung disease' OR 'chronic bronchitis'/syn OR 'chronic bronchitis' OR 'emphysema'/syn OR 'emphysema' OR (chronic* NEAR/3 bronchiti*):ab,ti OR (obstruct* NEAR/3 (pulmonary OR lung* OR airway* OR airflow* OR bronch* OR respirat*)):ab,ti#2moderat* OR sever* OR ‘serious’ OR ‘critical’ OR ‘end?stage’ OR ‘life?threatening’ OR ‘Moderate to severe’ OR stage?4 OR ‘moderate to very severe’ OR ‘gold b’ OR ‘gold d’ OR ‘gold-b’ OR ‘gold-d’ OR ‘gold stage b’ OR ‘gold stage d’ OR advance*#3#1 AND #2#4(utilit* NEAR/2 (measure* OR outcome* OR state* OR health OR score* OR weight* OR analysis)):ab,ti OR 'health utility index' OR 'hui' OR 'hrqol' OR 'hqol' OR 'quality of life'/exp OR 'quality of life' OR 'quality-of-life'/exp OR 'quality-of-life' OR qol OR utilit* NEXT/1 (score* OR value* OR evaluation*) OR health NEXT/2 utilit* OR ('health'/exp OR 'health' AND state NEXT/1 utilit*) OR hui OR (health NEXT/1 state* AND state* NEXT/1 preference*) OR 'quality adjusted life year'/exp OR 'quality adjusted life year' OR 'quality adjusted life' OR 'quality adjusted' NEXT/1 survival* OR qaly* OR qald* OR qale* OR qtime* OR 'disability adjusted life' OR daly* OR 'health survey'/exp OR 'health survey' OR hye* OR health*year*equivalent OR health NEAR/2 utility* OR 'wellbeing'/exp OR 'wellbeing' OR quality NEAR/2 well*being OR qwb OR willingness NEAR/2 pay OR standard NEAR/2 gamble OR disutili* OR time NEAR/2 trade*off OR tto OR 'discrete choice' NEXT/1 experiment* OR 'short form 36'/exp OR 'short form 36' OR 'sf36' OR 'sf-36' OR 'sf 36' OR 'short form 12'/exp OR 'short form 12' OR 'sf12' OR 'sf-12' OR 'sf 12' OR 'short form 6' OR 'sf6' OR 'sf-6' OR 'sf 6' OR 'euroqol' OR euro*qol OR 'eq5d' OR 'eq-5d' OR 'eq 5d' OR rosser OR (visual NEXT/1 analog* AND analog* NEXT/1 scale*) OR 'st george?s respiratory questionnaire' OR 'sgrq':ab,ti OR 'treatment satisfaction questionnaire for medication' OR 'tsqm':ab,ti OR ((treat* OR medi*) NEAR/3 satisfact*):ab,ti OR 'patient reported outcome*' OR 'tdi':ab,ti OR 'mrc':ab,ti OR 'medical research council dyspnoea scale':ab,ti OR 'emsci':ab,ti OR 'cat':ab,ti OR 'copd assessment test':ab,ti OR 'ccq':ab,ti OR 'clinical copd questionnaire':ab,ti OR 'chronic respiratory disease questionnaire':ab,ti OR 'crq':ab,ti#5#3 AND #4#6#5 AND ([conference review]/lim OR [editorial]/lim OR [letter]/lim OR [note]/lim OR [review]/lim)#7#5 NOT #6#8#7 AND [animals]/lim#9#7 NOT #8#10#9 AND ([embryo]/lim OR [fetus]/lim OR [newborn]/lim OR [infant]/lim OR [child]/lim OR [preschool]/lim OR [school]/lim OR [adolescent]/lim)#11#9 NOT #10#12#11 AND [english]/lim AND [2006-2017]/py#13(utilit* NEAR/2 (measure* OR outcome* OR state* OR health OR score* OR weight* OR analysis)):ab,ti OR 'health utility index' OR 'hui' OR utilit* NEXT/1 (score* OR value* OR evaluation*) OR health NEXT/2 utilit* OR ('health'/exp OR 'health' AND state NEXT/1 utilit*) OR hui OR (health NEXT/1 state* AND state* NEXT/1 preference*) OR 'quality adjusted life year'/exp OR 'quality adjusted life year' OR 'quality adjusted life' OR 'quality adjusted' NEXT/1 survival* OR qaly* OR qald* OR qale* OR qtime* OR 'disability adjusted life' OR daly* OR hye* OR health*year*equivalent OR health NEAR/2 utility* OR standard NEAR/2 gamble OR disutili* OR time NEAR/2 trade*off OR tto OR 'discrete choice' NEXT/1 experiment* OR 'short form 36'/exp OR 'short form 36' OR 'sf36' OR 'sf-36' OR 'sf 36' OR 'short form 12'/exp OR 'short form 12' OR 'sf12' OR 'sf-12' OR 'sf 12' OR 'short form 6' OR 'sf6' OR 'sf-6' OR 'sf 6' OR 'euroqol' OR euro*qol OR 'eq5d' OR 'eq-5d' OR 'eq 5d' OR rosser OR (visual NEXT/1 analog* AND analog* NEXT/1 scale*)#14#1 AND #13#15#14 AND ([conference review]/lim OR [editorial]/lim OR [letter]/lim OR [note]/lim OR [review]/lim)#16#14 AND [animals]/lim#17#14 AND ([embryo]/lim OR [fetus]/lim OR [newborn]/lim OR [infant]/lim OR [child]/lim OR [preschool]/lim OR [school]/lim OR [adolescent]/lim)#18#15 OR #16 OR #17#19#14 NOT #18 AND [2006-2020]/py#20#12 OR #19Table S2 Search Strategy for Humanistic Review Conducted for Cochrane#Search history#1MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees#2MeSH descriptor: [Bronchitis, Chronic] explode all trees#3MeSH descriptor: [Emphysema] explode all trees#4(chronic* near/3 bronchiti*):ti,ab,kw #5(emphysema* or copd or coad):ti,ab,kw #6(obstruct* near/3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)):ti,ab,kw #7#1 or #2 or #3 or #4 or #5 or #6 #8((utilit*) near/2 (measure* or outcome* or state* or health or score* or weight* or analysis)) #9“health utility index” or hui #10hrqol or hqol or hrql#11MeSH descriptor: [Quality of Life] explode all trees#12quality of life or qol #13utilit* next/1 (score* or value* or evaluation*) #14health next/2 utilit* or ('health' and state next/1 utilit*) #15“quality adjusted life year” or “quality adjusted life” #16MeSH descriptor: [Quality-Adjusted Life Years] explode all trees#17("quality adjusted" next/1 survival*) #18qaly* or qald* or qale* or qtime* #19“disability adjusted life” or daly* #20“health survey” or hye* or “health year equivalent” #21MeSH descriptor: [Health Care Surveys] explode all trees#22health near/2 utility* #23wellbeing or quality near/2 well*being or qwb #24willingness near/2 pay #25standard near/2 gamble #26disutili* #27time near/2 trade*off or tto #28"short form 36" or "sf36" or "sf-36" or "sf 36" #29"short form 12" or "sf12" or "sf-12" or "sf 12" #30"short form 6" or "sf6" or "sf-6" or "sf 6" #31euroqol or euro*qol or "eq5d" or "eq-5d" or "eq 5d" #32rosser #33qlq* #34“visual analogue scale” or (visual analog*) or ‘vas’ #35“st george?s respiratory questionnaire” OR “sgrq”#36“treatment satisfaction questionnaire for medication” OR “tsqm”OR ((treat* OR medi*) NEAR/3 satisfact*)#37“patient reported outcome*”#38“tdi”OR “mrc”OR “medical research council dyspnoea scale”OR “emsci”OR “cat”OR “copd assessment test”OR “ccq”OR “clinical copd questionnaire”OR “chronic respiratory disease questionnaire”OR “crq”#39#6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38#40#7 AND #39 AND Publication Year from 2006 to 2020Table S3 Search Strategy for Humanistic Review Conducted for MEDLINE? In-Process#Search history#1Search “chronic obstructive lung disease”#2Search (“chronic bronchitis” OR emphysema)#3Search (chronic*) AND bronchiti*#4Search (obstruct*[Title/Abstract]) AND (pulmonary OR lung* OR airway* OR airflow* OR bronch* OR respirat*[Title/Abstract])#5Search #1 OR #2 OR #3 OR #4#6“quality of life” OR “quality of life” OR “quality-of-life” OR “quality-of-life” OR qol#7utilit* AND (score* OR value* OR evaluation* OR health)#8health AND state AND utilit*#9health AND state* AND preference*#10hui OR “quality adjusted life year” OR “quality adjusted life year” OR “quality adjusted life” OR (“quality adjusted” AND survival*)#11qaly* OR qald* OR qale* OR qtime* OR “disability adjusted life” OR daly* OR?”health survey” OR “health survey” OR hye* OR health*year*equivalent OR (health AND utility*)#12wellbeing OR (quality AND well*being) OR qwb#13(willingness AND pay) OR (standard AND gamble) OR disutili* OR (time AND trade*off) OR tto OR (“discrete choice” AND experiment*)#14“short form 36”OR sf36 OR “sf-36” OR “sf 36” OR “short form 12” OR sf12 OR “sf-12” OR “sf 12” OR “short form 6” OR sf6 OR “sf-6” OR “sf 6” OR euroqol OR euro*qol OR “eq5d” OR “eq-5d” OR “eq 5d” OR rosser#15visual AND analog* AND scale*#16“st george?s respiratory questionnaire” OR “sgrq”#17“treatment satisfaction questionnaire for medication” OR “tsqm”OR ((treat* OR medi*) NEAR/3 satisfact*)#18“patient reported outcome*”#19“tdi”OR “mrc”OR “medical research council dyspnoea scale”OR “emsci”OR “cat”OR “copd assessment test”OR “ccq”OR “clinical copd questionnaire”OR “chronic respiratory disease questionnaire”OR “crq”#20#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19#21Search #5 AND #20#22Search #21 AND (inprocess[sb] OR pubstatusaheadofprint)Table S4 Patient Characteristics of COPD Studies Included in the HRQoL ReviewAuthor Name and YearnGOLD SeverityPredicted FEV1 (%)Population AnalyzedStudyTypeAge (years)MaleNon-smokerCurrent SmokerEx-smokerSmoking Pack-yearsMean (SD) or median (IQR)Mean (SD) or Median (IQR)%%%%Mean (SD) or Median (IQR)AustraliaKyoong 2006113Moderate55.5 (3.1)GOLD moderate in COPD-X moderate patientsCross-sectional67.5 (4.7)6956.9 (24.0)Kyoong 200619Severe44.9 (1.5)GOLD severe in COPD-X moderate patientsCross-sectional67.2 (10.7)2250.0 (39.1)Kyoong 2006111Severe36.1 (2.5)GOLD severe in COPD-X severe patientsCross-sectional72.3 (3.2)6440.2 (21.3)Kyoong 200616Very severe22.0 (4.5)GOLD very severe in COPD-X severe patientsCross-sectional67.7 (9.4)8350.0 (10.5)McGlone 2006265Moderate to very severe46 (16)Participation in non-walking activitiesCross-sectional69.0 (8.0)422755 (25)McGlone 2006259Moderate to very severe45 (16)No participation in non-walking activitiesCross-sectional72.0 (8.0)793559 (34)Mckellar 2008324Severe38.4 (15.3)Severe COPD: ≤2 admissionsCross-sectional65.06701783Mckellar 200838Very Severe29.4 (12.5)Very severe COPD: ≥3 admissionsCross-sectional686301387Sloots?2017482Severe39 (31–45)Severe COPDRetrospective study73.4 (9.9)462.48.589.040Williams 2017584Moderate to very severe47.9 (16.6)Moderate to very severe COPD (>80 % of patients)Cross-sectional69.7 (8.9)56CanadaChen 2018691GOLD II–IV (>80%)51.1 (21.2)Moderate to very severe (>80%)Cross-sectional70.7 (9.5)5741.5 (25.9)Gupta 20167 716GOLD I–III+82.3 (19.3)Overall (~45 % of patients with moderate to very severe COPD)Prospective6027.218.354.5Shah 20208240GOLD II–IVModerate to very severe COPDCross-sectional66.7 (10.2)54ChinaChen 201391421Mild to very severeGOLD A–D (>80 % of patients with moderate to very severe COPD)Cross-sectionalChen 201410154Severe to very severe32.7 (9.2)Severe to very severeCross-sectional72.9 (8.1)993.312.384.4Gao 201311218Mild to very severe47.3 (14.3)Overall (>70 % of patients with moderate to very severe COPD)Case-control study66.7 (7.4)848.364.727.135.0 (23.5)Lou 2012121100Mild to very severe45.2 (10.8)Overall (>80 % of patients with moderate to very severe COPD)Cross-sectional + case-control63.2 (40–75)7555.520.524.0Tao 201713167Mild to very severe48.4 (18.8)Overall (>90 % of patients with moderate to very severe COPD)Cross-sectional69.1 (6.9)6434.118.047.9Wiklund 201014286Mild to very severe52 (22.1)Overall (>50 % of patients with severe to very severe COPD)Cross-sectional68.1 (9.2)82Wu 201515678Moderate to very severe54.5 (23)Overall (~80 % of patients with moderate to very severe COPD)Cross-sectional70.4 (10.1)7319.4Xiang 201516142GOLD I–IVModerate to very severe COPD (>80 % of patients)Case-control73.9 (6.2)83Yang 202017210NRPatients with acute exacerbationsCross-sectional71.1 (12.2)86Zhang 20151833GOLD III–IV35.4 (6.5)GOLD III–IV groupCase-control study68.8 (11.2)67Zhou 20186372GOLD II–IV48.6 (18.9)Overall (>80 % of patients with moderate to very severe COPD)Cross-sectional62.2 (8.3)8640 (32.2)FranceBeaumont 20181950GOLD III–IV35.7 (8.8)Severe to very severeProspective observational66.7 (7.8)Le Rouzic 201820835GOLD II–IV47.7 (15.6)Moderate to very severe COPDProspective observational66.3 (9.6)8024.775.344.4 (19.8)GermanyKühl 200821143Moderate to very severe62.9 (9.6) to 26.4 (2.8)Moderate to very severe COPDCross-sectional67 (9.5)784.921.773.4Menn 201022 117GOLD III–IVSevere COPD (≤70% of patients)Prospective observational67.56316Mewes 201623502Mild to very severeOverall (>95 % of patients with moderate to very severe COPD)Cross-sectional59.7 (8.7)4751679Vaske 201724444Mild to very severeOverall (>95 % of patients with moderate to very severe COPD)Cross-sectional60.8 (8.0)49Von Siemens 201925948GOLD II62.6 (8.3)Moderate COPDProspective65.7 (8.4)6028.650.9 (37.5)Von Siemens 201925863GOLD III40.7 (5.6)Severe COPDProspective65 (8.2)6121.848.4 (34.8)Von Siemens 201925241GOLD IV24.8 (3.9)Very severe COPDProspective62.2 (7.9)6514.548.5 (33.5)Von Siemens 201925567Overall (GOLD I–IV)47.6 (16.6)GOLD BProspective66.2 (8.1)6222.953.0 (36.9)Von Siemens 201925523Overall (GOLD I–IV)42.4 (15.2)GOLD DProspective64.6 (8.0)5817.849.9 (36.8)Wacker 2016262291Mild to very severe52.5 (18.6)Overall (>90 % of patients with moderate to very severe COPD)Cross-sectional65.1 (8.4)616.624.768.8ItalyBonfitto 20172735NR51.7 (11.8)Patients with acute exacerbationProspective observational75.3 (6.45)57Braido 201528694Moderate64.1 (9.1)Moderate COPDCross-sectional70.2 (9.7)759.727.862.5Di Marco 200629202Mild to very severe (>80%)54.0 (1.0)Overall (>85 % of patients with moderate to very severe COPD)Case-control study68.0(1.0)77Dignani 201630102Mild to severe59.3 (20.6)Overall (>85% of patients with moderate to very severe COPD)Cross-sectional73.0 (IQR 10)759.813.776.5Ivziku 20193180GOLD I–IVOverall (>55% of patients with severe to very severe COPD)Cross-sectional76.4 (7.33)56SpainAlmadana 20123234NRNRProspective observationalBalcells 200933342Moderate to very severe 47.0 (16.5)Overall (~95% of patients with moderate to very severe COPD)Cross-sectional67.5 (8.5)930.642.457.065.9 (41.2)Carrasco-Garrido 20063410,711Mild to severe (SEPAR criteria)35.9 (10.0)OverallObservational64.1 (9.7)7623.219.057.8Esteban 200935 304MildGOLD/ATS-ERS; mild COPDProspective observational66.1 (8.9)Esteban 200935267ModerateGOLD/ATS-ERS; moderate COPDProspective observational67.5 (8.1)Esteban 20093540SevereGOLD/ATS-ERS; severe COPDProspective observational65.7 (6.8)Feliz-Rodriguez 20133645Mild to severe (≥80%)51.0 (17.0)Overall (>85 % of patients with moderate to very severe COPD) Prospective observational71 (10.0)692564251.0 (27.0)Fernández-García et al 202037253Mostly severe42.1 (14.2)Patients with severe exacerbationsProspective observational68.9 (9.8)773.637.958.554.2 (29.1)Izquierdo 2009383619 GOLD I–IVOverall (~80 % of patients with moderate to very severe COPD)OverallCross-sectional67.0 (10.8)7520.522.756.7Lopez-Campos 2015391212Mild to very severe61.6 (20.2)Mild to very severeCross-sectional66.4 (9.7)7926.2Martin 2008409405Mild to severe55.1 (14.3)Overall (66 % of patients with moderate to severe COPD)Cross-sectional67.8 (9.8)8016.022.661.4Medinas Amoros 20094164Moderate to very severe38.2 (16.6)Moderate to very severe COPDCross-sectional70.1 (9.0)Merino 201942386GOLD I–IV66.7 (22.3)Overall (~90 % of patients with moderate to very severe COPD)Cross-sectional71.8 (10.3)7613.716.769.6Miravitlles 2011 (ESFERA Study)43346Mild to very severe46.9 (17.0)Overall (>95 % of patients with moderate to very severe COPD)Prospective observational68.5 (9.5)9119.350.9 (29.5)Miravitlles 201544 497Mild to severe47.1 (17.5)Patients with Moderate to severe exacerbationProspective observational68.7 (9.2)9029.652.7 (30.5)Miravitlles 200745222GOLD stage II or higher49.2 (15.4)Moderate to very severe COPDProspective observational68.2 (9.9)9551.4 (28.3)Miravitlles 200946827Mild to very severe 54.6 (17.7)Overall (>95 % of patients with moderate to very severe COPD)Cross-sectional69.0 (10.0)8721.675.147.0 (28.0)Moro 2009 (MUVICE study)471786Mild to severe (according to SEPAR criteria)58.5 (13.9)Mild to severe COPDCross-sectional66.5 (11.0)057.316.126.733.8 (17.5)Pinto 20104875Mild to very severe77.5 (26.0)Overall (31 % of patients with COPD)Cross-sectional60.4 (18.8)6514.740Ramon 2017495969GOLD A–D50.7 (17.2)Overall (>95% of patients with moderate to very severe COPD)Retrospective67.5 (9.6)8623.4Soler-Catalu?a 201650605Mild to very severe53.3 (20.7)Overall (>90% of patients with moderate to very severe COPD)Prospective observational66.9 (8.7)6128.941 (23.2)Soler-Catalu?a 201650122Mild to severe 50.5 (19.4)Overall (>90% of patients with moderate to very severe COPD)Prospective observational68.9 (9.2)9122.153.1 (29.7)Spain, Italy, and GermanyCelli 201751334GOLD I–IVOverall (>85% of patients with moderate to very severe COPD)Cross-sectional5838.6UKKnolle 20115214SevereSevere COPD: patients admittedProspective observational74.1Lawrence 201753370GOLD A–DOverall (>89% GOLD B–D)Prospective observational70.2 (8.8)6530.046.0Lawrence 201753107ModerateGOLD BProspective observational6736.545.0Mackay 20125475Moderate to very severe47.9(16.3)OverallProspective observational71.3(8.4)572752.2(39.9)Mi 201755112GOLD IVVery severe COPDCross-sectional71.4 (8.7)61Parshall 200856127Mild to very severe 49.7 (18.6)Overall (~90 % of patients with moderate to very severe COPD)Prospective observational69.4 (8.2)63Roberts 20125718Moderate to very severe53.0Moderate to very severe COPDProspective observational68.0 (8.0)555.527.866.7Yeo 20065827Mild to severeOverall (>60 % of patients with moderate to severe COPD)Prospective observational76.0 (4.4)59USAAdams 201259158Mild to very severe41 (16)GOLD A–DCross-sectional66 (9)78Coultas 201360259Moderate to very severe (>80%)GOLD stage II–IVCross-sectional68.7 (9.5)51Dhamane 201661938ModerateModerate COPDCross-sectional57.1 (9.7)5317.743.638.7Dhamane 201661175SevereSevere COPDCross-sectional58.3 (9.6)5514.339.446.3Felker 201062 25ModerateModerate COPDCross-sectional68.0 (10.6)Felker 20106238Severesevere COPDCross-sectional66.9 (8.9)Felker 20106226Very severeVery severe COPDCross-sectional67.5 (8.9)Han 2013631109Moderate68 (13)GOLD BProspective observational62(9)535554 (30)Han 201363173Severe41 (7)GOLD C1Prospective observational66(8)603450 (24)Han 20136338Severe68 (12)GOLD C2Prospective observational65 (8)322144 (19)Han 20136310Severe40 (7)GOLD C3Prospective observational65 (5)601062 (22)Han 2013631182Very severe41 (7)GOLD D1Prospective observational65 (8)593257 (29)Han 201363252Very severe65 (11)GOLD D2Prospective observational61 (9)442851 (27)Han 201363403Very severe32(10)GOLD D3Prospective observational63 (8)532855 (27)Jackson 20146486Moderate to very severe49.0(12.9)High pain quartileCross-sectional64.9 (9.6)Jackson 20146475Moderate to very severe (FEV1 <70%)41.9 (13.1)Low pain quartileCross-sectional70.1 (8.7)Jain 20126541Moderate to severe53.6 (15.8)Moderate to severe COPDProspective observational65.1 (8.8)61.8 (45.7)Joo 20086644GOLD III–IVSevere to very severe COPDProspective observational71.5 (7.2)4.518.277.355.9 (28.5)Kapella 200667 62Moderate to severe46.1 (18.4)WomenCross-sectional68.7 (6.7) 0Kapella 200667 62Moderate to severe44.5 (17.9)MenCross-sectional69.5 (5.8) 100Krishnan 200668495Moderate to very severe66.2 (12.4)Moderate to severe COPDCross-sectional64.2 (10.0)5524.227.148.727.6 (26.5)Lambert 201769 2383 Moderate to severe49 (19)Normal/overweight patientsProspective observational63 (9)574353 (28)Lambert 201769748Moderate to severe53 (17)Obesity Class IProspective observational64 (9)573753 (27)Lambert 201769316Moderate to severe53 (16)Obesity Class IIProspective observational62 (8)423456 (28)Lambert 201769184Moderate to severe53 (14)Obesity Class IIIProspective observational61 (9)384051 (27)Leidy 201170 222Moderate to very severe50.5 (20.4)Acute group Prospective observational65.1 (10.5)4732Leidy 201170188Moderate to very severe51.2 (19.6)Stable group Prospective observational65.8 (9.7)4831Martinez 2016711927Mild to very severe54.9(22.5)Older adultsCross-sectional71.0 (4.0)5721.557.2(29.9)Martinez 2016712170Mild to very severe58.2 (22.9)Middle-aged adultsCross-sectional58.3 (4.2)5557.349.1 (24.5)Omachi 2013721202Moderate to very severe62 (23)OverallProspective observational58.2 (6.2)43Paulin 20127384Moderate to severe55Moderate to severe COPDProspective observational695856Pinto-Plata 201374 31Moderate to very severe35 (12)Non-survivorProspective observational67 (10)68Pinto-Plata 20137429Moderate to very severe45 (15)SurvivorProspective observational68 (7)59Solem 201375 190Severe48.7 (12.0)Severe COPDCross-sectional + Retrospective chart review67.4 (9.8)507.9 27.964.2Solem 201375 124Very severe40.1 (14.8)Very severe COPDCross-sectional + Retrospective chart review68.8 (9.2)542.427.470.2Talley 20097636Moderate to very severe (FEV1 <80%)Moderate to very severe COPDCross-sectional59 (12)4736.5 (23.25)Vaz Fragoso 201677 10131Mild to severe COPDOverall (>90 % of patients with moderate to severe COPD)Prospective observational59.6 (9.0)5352.347.744.3 (24.9)Abbreviations: ATS, American Thoracic Society; COPD, chronic obstructive pulmonary disease; COPD-X, Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease; ERS, European Respiratory Society; FEV1, forced expired volume in one second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HRQoL, health-related quality of life; IQR, interquartile range; NR, not reported; SD, standard deviation; SEPAR, Spanish Society of Pulmonology and Thoracic Surgery.Table S5 Scoring From Critical Appraisal of Individual Studies Included in the HRQoL Review Using Gill and Feinstein Criteria CriteriaDid the investigator give a definition of quality of life?Did the investigators state the domains they will measure as components of quality of life?Did the investigators give reasons for choosing the instrument they used?Did the investigator aggregate results from multiple items, domains or instruments into asingle composite score for quality of life?Were patients asked to give their own global rating for quality of life?Was overall quality of life distinguished from health-related quality of life?Were the patients invited to supplement the items listed in the instruments offered by theinvestigators that they considered relevant for their quality of life?If so, were these supplemental items incorporated into the final rating?Were patients allowed to indicate which items were personally important to them?If so, were the importance ratings incorporated into the final rating?Summary scoreTotal criteria compliedKyoong 200610101000NA0NA252McGlone 200621101010NA0NA504Mckellar 200830101000NA0NA252Sloots?201740100NA0NANANANA12.51Williams 201750101000NA0NA252Chen 2018780101010NA0NA37.53Gupta 201670101000NA0NA252Shah 20208010101NANANANA37.53Chen 201390000000NA0NA00Chen 2014100111000NA0NA37.53Gao 2013110100000NA0NA12.51Lou 2012120101000NA0NA252Tao 2017130101000NA0NA252Wiklund 2010140100000NA0NA12.51Wu 2015150111000NA0NA37.53Xiang 2015161101000NA0NA37.53Yang 2020170101000NA0NA252Zhang 2015180111000NA0NA37.53Zhou 201860100000NA0NA12.51Beaumont 2018190101000NA0NA252Le Rouzic 2018200101000NA0NA252Kühl 2008210101010NA0NA37.53Menn 2010220111000NA0NA37.53Mewes 2016230111000NA0NA37.53Vaske 2017240111000NA0NA37.53Von Siemens 2019250101000NA0NA252Wacker 2016260101000NA0NA252Bonfitto 2017270101000NA0NA252Braido 2015280111100NA0NA504Di Marco 2006290111000NA0NA37.53Dignani 2016301101000NA0NA37.53Ivziku 2019310111100NA0NA504Almadana 2012320000000NA0NA00Balcells 2009330101000NA0NA252Carrasco-Garrido 2006340100000NA0NA12.51Esteban 2009790101000NA0NA252O’Reilly 2007800101000NA0NA252Feliz-Rodriguez 2013360101000NA0NA252Fernández-García et al 2020370001000NA0NA12.51Izquierdo 2009380101000NA0NA252Lopez-Campos 2015390100000NA0NA12.51Martin 2008400100000NA0NA12.51Medinas Amoros 2009411101000NA0NA37.53Merino 2019420100000NA0NA12.51Miravitlles 2011 (ESFERA Study)430101000NA0NA252Miravitlles 2015440101000NA0NA252Miravitlles 2007450101000NA0NA252Miravitlles 2009460101000NA0NA252Moro 2009 (MUVICE study)470101000NA0NA252Pinto 2010480101000NA0NA252Ramon 2017490000100NA0NA12.51Soler-Catalu?a 2016500100000NA0NA12.51Celli 2017510100110NA0NA37.53Knolle 2011520000000NA0NA00Lawrence 2017530101000NA0NA252Mackay 2012540000000NA0NA00Mi 2017550100000NA0NA12.51Parshall 2008560110000NA0NA252Roberts 2012570000000NA0NA00Yeo 2006580100000NA0NA12.51Adams 201259000000NANA0NA00Coultas 2013600001000NA0NA12.51Dhamane 2016610100000NA0NA12.51Felker 201062 0100000NA0NA12.51Vaz Fragoso 2016770100000NA0NA12.51Han 2013630101000NA0NA252Jackson 201464010000NANA0NA12.51Jain 2012650100000NA0NA12.51Joo 2008660101000NA0NA252Kapella 2006670100000NA0NA12.51Krishnan 2006681100000NA0NA252Lambert 2017690100000NA0NA12.51Leidy 2011700101100NA0NA37.53Starkie 2011810100000NA0NA12.51Martinez 2016710101000NA0NA252Omachi 2013720100000NA0NA12.51Paulin 2012730100000NA0NA12.51Pinto-Plata 2013740000000NA0NA00Steer 201282011000NANA0NA252Solem 201375011001NANANANA37.53Talley 2009761101010NA1NA62.55Kelly 2011830110000NA0NA252Total number of studies6721347570010?References1.Kyoong A, Mol S, Guy P, et al. Comparison of Australian and international guidelines for grading severity of chronic obstructive pulmonary disease. Intern Med J. 2006;36(8):506-512.2.McGlone S, Venn A, Walters EH, Wood-Baker R. Physical activity, spirometry and quality-of-life in chronic obstructive pulmonary disease. COPD. 2006;3(2):83-88.3.McKellar A, Cottrell WN, Whelan A. BODE score is a useful predictor of hospital admission in rural patients with chronic obstructive pulmonary disease. Respirology. 2008;13(3):438-443.4.Sloots JM, Barton CA, Buckman J, et al. The predictive value of an adjusted COPD assessment test score on the risk of respiratory-related hospitalizations in severe COPD patients. Chron Respir Dis. 2017;14(1):72-84.5.Williams MT, John D, Frith P. Comparison of the dyspnoea-12 and multidimensional dyspnoea profile in people with COPD. The European respiratory journal. 2017;49(3):1600773.6.Zhou Z, Zhou A, Zhao Y, Duan J, Chen P. A comparison of the assessment of health status between CCQ and CAT in a Chinese COPD clinical population: a cross-sectional analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:1675.7.Gupta N, Pinto L, Benedetti A, et al. The COPD assessment test: can it discriminate across COPD subpopulations? Chest. 2016;150(5):1069-1079.8.Shah A, Ayas N, Tan WC, et al. Sleep quality and nocturnal symptoms in a community-based COPD cohort. COPD. 2020;17(1):40-48.9.Chen Y, Yao W, Kang J, et al. Distribution and significance of GOLD 2011 disease severity classification in patients with COPD in China: a national cross-sectional survey. The European respiratory journal. 2013;42:P1870.10.Chen J, Wong CK, McGhee SM, Pang PK, Yu WC. A comparison between the EQ-5D and the SF-6D in patients with chronic obstructive pulmonary disease (COPD). PLoS One. 2014;9(11):e112389.11.Gao Y, Hou Q, Wang H. Assessment of health status in patients with newly diagnosed chronic obstructive pulmonary disease. PLoS One. 2013;8(12):e82782.12.Lou P, Zhu Y, Chen P, et al. Prevalence and correlations with depression, anxiety, and other features in outpatients with chronic obstructive pulmonary disease in China: a cross-sectional case control study. BMC Pulm Med. 2012;12:53.13.Tao YX, Wang L, Dong XY, et al. Psychometric properties of the Physical Activity Scale for the Elderly in Chinese patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:105-114.14.Wiklund I, Berry, P, Lu, KX, Fang, J, Fu, C. The Chinese translation of COPD assessment test? (CAT) provides a valid and reliable measurement of COPD health status in Chinese COPD patients. Am J Respir Crit Care Med. 2010;181(1).15.Wu M, Zhao Q, Chen Y, Fu C, Xu B. Quality of life and its association with direct medical costs for COPD in urban China. Health Qual Life Outcomes. 2015;13:57.16.Xiang Y, Wong T, Tsoh J, et al. Quality of life in older patients with chronic obstructive pulmonary disease (COPD) in Hong Kong: a case‐control study. Perspect Psychiatr Care. 2015;51(2):121-127.17.Yang Y, Li Q, Mao J, Mao Z. Fatigue and health‐related quality of life among patients with chronic obstructive pulmonary disease in China. Clin Respir J. 2020;14(2):109-115.18.Zhang Y, Tu YH, Fei GH. The COPD assessment test correlates well with the computed tomography measurements in COPD patients in China. Int J Chron Obstruct Pulmon Dis. 2015;10:507-514.19.Beaumont M, Couturaud F, Jego F, et al. Validation of the French version of the London Chest Activity of Daily Living scale and the dyspnea-12 questionnaire. Int J Chron Obstruct Pulmon Dis. 2018;13:1399-1405.20.Le Rouzic O, Roche N, Cortot A, et al. Defining the “frequent exacerbator” phenotype in COPD: a hypothesis-free approach. Chest. 2018;153(5):1106-1115.21.Kühl K, Schurmann W, Rief W. Mental disorders and quality of life in COPD patients and their spouses. Int J Chron Obstruct Pulmon Dis. 2008;3(4):727-736.22.Menn P, Weber N, Holle R. Health-related quality of life in patients with severe COPD hospitalized for exacerbations – comparing EQ-5D, SF-12 and SGRQ. Health Qual Life Outcomes. 2010;8:39.23.Mewes R, Rief W, Kenn K, Ried J, Stenzel N. Psychological predictors for health-related quality of life and disability in persons with chronic obstructive pulmonary disease (COPD). Psychol Health. 2016;31(4):470-486.24.Vaske I, Kenn K, Keil DC, Rief W, Stenzel NM. Illness perceptions and coping with disease in chronic obstructive pulmonary disease: effects on health-related quality of life. J Health Psychol. 2017;22(12):1570-1581.25.von Siemens SM, Jorres RA, Behr J, et al. Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study. Respir Res. 2019;20(1):30.26.Wacker ME, Jorres RA, Karch A, et al. Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulm Med. 2016;16(1):70.27.Bonfitto I, Moniello G, Pascucci M, et al. Mood disorders in elderly patients hospitalized for acute exacerbation of COPD. J Gerontol. 2017;4:13.28.Braido F, Baiardini I, Scichilone N, et al. Disability in moderate chronic obstructive pulmonary disease: prevalence, burden and assessment – results from a real-life study. Respiration. 2015;89(2):100-106.29.Di Marco F, Verga M, Reggente M, et al. Anxiety and depression in COPD patients: the roles of gender and disease severity. Respir Med. 2006;100(10):1767-1774.30.Dignani L, Toccaceli A, Lucertini C, Petrucci C, Lancia L. Sleep and quality of life in people with COPD: a descriptive-correlational study. Clin Nurs Res. 2016;25(4):432-447.31.Ivziku D, Clari M, Piredda M, De Marinis MG, Matarese M. Anxiety, depression and quality of life in chronic obstructive pulmonary disease patients and caregivers: an actor–partner interdependence model analysis. Qual Life Res. 2019;28(2):461-472.32.Almadana V, Sanchez, J, Gómez-Bastero, A, Valido, A, Pavón, M, Montemayor, T. COPD assessment test (CAT) in the evaluation of COPD. The European respiratory journal. 2012;40.33.Balcells E, Anto JM, Gea J, et al. Characteristics of patients admitted for the first time for COPD exacerbation. Respir Med. 2009;103(9):1293-1302.34.Carrasco Garrido P, de Miguel Diez J, Rejas Gutierrez J, et al. Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. Health Qual Life Outcomes. 2006;4(1):31.35.Esteban C, Quintana JM, Egurrola M, et al. Classifying the severity of COPD: are the new severity scales better than the old? Int J Tuberc Lung Dis. 2009;13(6):783-790.36.Feliz-Rodriguez D, Zudaire, S, Carpio, C, Martínez, E, Gómez-Mendieta, A, Santiago, A, Alvarez-Sala, R, García-Río, F. Evolution of the COPD Assessment Test score during chronic obstructive pulmonary disease exacerbations: determinants and prognostic value. Can Respir J. 2013;20(5):e92-e97.37.Fernández-García S, Represas-Represas C, Ruano-Ravi?a A, et al. Social and clinical predictors associated with prolonged hospital stays for patients with severe exacerbation of chronic obstructive pulmonary disease. Rev Clin Esp. 2020;220(2):79-85.38.Izquierdo JL, Barcina C, Jimenez J, Munoz M, Leal M. Study of the burden on patients with chronic obstructive pulmonary disease. Int J Clin Pract. 2009;63(1):87-97.39.Lopez-Campos JL, Fernandez-Villar A, Calero-Acuna C, et al. Evaluation of the COPD Assessment Test and GOLD patient types: a cross-sectional analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:975-984.40.Martin A, Rodriguez-Gonzalez Moro JM, Izquierdo JL, Gobartt E, de Lucas P. Health-related quality of life in outpatients with COPD in daily practice: the VICE Spanish Study. Int J Chron Obstruct Pulmon Dis. 2008;3(4):683-692.41.Medinas Amoros M, Mas-Tous C, Renom-Sotorra F, Rubi-Ponseti M, Centeno-Flores MJ, Gorriz-Dolz MT. Health-related quality of life is associated with COPD severity: a comparison between the GOLD staging and the BODE index. Chron Respir Dis. 2009;6(2):75-80.42.Merino M, Villoro R, Hidalgo-Vega ?, Carmona C. Health-related quality of life of patients diagnosed with COPD in Extremadura, Spain: results from an observational study. Health Qual Life Outcomes. 2019;17(1):1-10.43.Miravitlles M, Izquierdo I, Herrejon A, et al. COPD severity score as a predictor of failure in exacerbations of COPD. The ESFERA study. Respir Med. 2011;105(5):740-747.44.Miravitlles M, Garcia-Sidro P, Fernandez-Nistal A, et al. The chronic obstructive pulmonary disease assessment test improves the predictive value of previous exacerbations for poor outcomes in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:2571-2579.45.Miravitlles M, Molina J, Naberan K, Cots JM, Ros F, Llor C. Factors determining the quality of life of patients with COPD in primary care. Ther Adv Respir Dis. 2007;1(2):85-92.46.Miravitlles M, Llor C, de Castellar R, Izquierdo I, Baro E, Donado E. Validation of the COPD severity score for use in primary care: the NEREA study. The European respiratory journal. 2009;33(3):519-527.47.Moro JMR-G, Izquierdo JL, Antón E, de Lucas P, Martín A, Group MS. Health-related quality of life in outpatient women with COPD in daily practice: the MUVICE Spanish study. Respir Med. 2009;103(9):1303-1312.48.Pinto JMS, González JR, Arenillas JIC, Nogueras AMM, Gómez FPG. The health-related quality of life of patients with chronic obstructive pulmonary disease and asthma evaluated by the SGRQ. Rev Port Pneumol. 2010;16(4):543-558.49.Ramon MA, Esquinas C, Barrecheguren M, et al. Self-reported daily walking time in COPD: relationship with relevant clinical and functional characteristics. Int J Chron Obstruct Pulmon Dis. 2017;12:1173-1181.50.Soler-Catalu?a JJ, Sauleda J, Valdés L, et al. Prevalence and perception of 24-hour symptom patterns in patients with stable chronic obstructive pulmonary disease in Spain. Arch Bronconeumol. 2016;52(6):308-315.51.Celli B, Blasi F, Gaga M, et al. Perception of symptoms and quality of life–comparison of patients’ and physicians’ views in the COPD MIRROR study. Int J Chron Obstruct Pulmon Dis. 2017;12:2189.52.Knolle M, Challis, B, Pearce, L, Laroche, C, Pulimood, T. Admission avoidance by hospital at home for exacerbations of COPD by a nurse led team in the east of England. Am J Respir Crit Care Med. 2011;183(1):1073-1449.53.Lawrence PJ, Kolsum U, Gupta V, et al. Characteristics and longitudinal progression of chronic obstructive pulmonary disease in GOLD B patients. BMC Pulm Med. 2017;17(1):42.54.Mackay A, Donaldson, GC, Patel, AR, Jones, PW, Hurst, JR, Wedzicha, JA. Usefulness of the chronic obstructive pulmonary disease assessment test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med. 2012;185:1218-1224.55.Mi E, Mi E, Ewing G, et al. Associations between the psychological health of patients and carers in advanced COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2813.56.Parshall MB, Mapel DW, Rice L, Williams A, O'Reilly J. Predictive validity of short-form health survey [36 items] scales for chronic obstructive pulmonary disease exacerbation. Heart Lung. 2008;37(5):356-365.57.Roberts NJ, Patel IS, Kidd L, Lawrence M, Booth J. P32?Does disease severity affect patient activation scores in COPD? Thorax. 2012;67(Suppl 2):A77.71-A77.58.Yeo J, Karimova G, Bansal S. Co-morbidity in older patients with COPD–its impact on health service utilisation and quality of life, a community study. Age Ageing. 2006;35(1):33-37.59.Adams S, Fan V, Nguyen H, et al. Clinical outcomes in chronic obstructive pulmonary disease are associated with perception of dyspnea more than exacerbation risk or disease severity measured by lung function. Chest. 2012;142(4):676A.60.Coultas D, Russo, R, Peoples, J, Jackson, BE, Uhm, M, Singh, KP, Ashmore, J, Bae, S. Self-reported measures of physical activity and health-related outcomes among patients with COPD. Am J Respir Crit Care Med. 2013;187.61.Dhamane AD, Witt EA, Su J. Associations between COPD severity and work productivity, health-related quality of life, and health care resource use: a cross-sectional analysis of national survey data. J Occup Environ Med. 2016;58(6):e191-197.62.Felker B, Bush KR, Harel O, Shofer JB, Shores MM, Au DH. Added burden of mental disorders on health status among patients with chronic obstructive pulmonary disease. Prim Care Companion J Clin Psychiatry. 2010;12(4):PCC.09m00858.63.Han MK, Muellerova H, Curran-Everett D, et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. The Lancet Respiratory medicine. 2013;1(1):43-50.64.Jackson B, Coultas, DB, Russo, R, Peoples, J, Uhm, M, Singh, KP, Ashmore, J, Bae, S. Health impact of pain among a representative sample of outpatients with COPD. Am J Respir Crit Care Med. 2014;189.65.Jain N, Fulambarker, A, Copur, AS, Nadeem, R, Ghadai, A, Rishi, MA, Bawaadam, HS, Sethi, A, Quwatli, Z. The effect of hyperinflation measured by IC/TLC ratio on health status of COPD patients. Am J Respir Crit Care Med. 2012;185:A1516.66.Joo MJ, Lee TA, Bartle B, van de Graaff WB, Weiss KB. Patterns of healthcare utilization by COPD severity: a pilot study. Lung. 2008;186(5):307-312.67.Kapella MC, Larson JL, Patel MK, Covey MK, Berry JK. Subjective fatigue, influencing variables, and consequences in chronic obstructive pulmonary disease. Nurs Res. 2006;55(1):10-17.68.Krishnan G, Grant BJ, Muti PC, et al. Association between anemia and quality of life in a population sample of individuals with chronic obstructive pulmonary disease. BMC Pulm Med. 2006;6:23.69.Lambert AA, Putcha N, Drummond MB, et al. Obesity Is associated with increased morbidity in moderate to severe COPD. Chest. 2017;151(1):68-77.70.Leidy NK, Wilcox TK, Jones PW, et al. Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am J Respir Crit Care Med. 2011;183(3):323-329.71.Martinez CH, Diaz AA, Parulekar AD, et al. Age-related differences in health-related quality of life in COPD: an analysis of the COPDGene and SPIROMICS cohorts. Chest. 2016;149(4):927-935.72.Omachi TA, Gregorich SE, Eisner MD, et al. Risk adjustment for health care financing in chronic disease: what are we missing by failing to account for disease severity? Med Care. 2013;51(8):740-747.73.Paulin L, McCormack, MC, Diette, GB, Belli, AJ, Williams, D, Matsui, EC, Curtin-Brosnan, J, Aloe, C, Peng, RD, Breysse, P, Hansel, N. Indoor nitrogen dioxide concentrations are associated with worsening dyspnea in former smokers with COPD. Am J Respir Crit Care Med. 2012;185:A6633.74.Pinto-Plata V, Tesfaigzi, Y, Divo, M, Owen, C, Petersen, H, Wang, Y, Holloway, D, Sanchez, P, Calhoun, V, Martin, S, Celli, BR. Plasma metabolic profile in COPD patients. Association to survival. Am J Respir Crit Care Med. 2013;187:A1519.75.Solem CT, Sun SX, Sudharshan L, Macahilig C, Katyal M, Gao X. Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:641-652.76.Talley CH, Wicks MN. A pilot study of the self-reported quality of life for patients with chronic obstructive pulmonary disease. Heart Lung. 2009;38(2):141-150.77.Vaz Fragoso CA, McAvay G, Van Ness PH, et al. Phenotype of spirometric impairment in an aging population. Am J Respir Crit Care Med. 2016;193(7):727-735.78.Chen Y-W, Camp PG, Coxson HO, et al. A comparison of pain, fatigue, dyspnea and their impact on quality of life in pulmonary rehabilitation participants with chronic obstructive pulmonary disease. COPD. 2018;15(1):65-72.79.Esteban C, Quintana J, Moraza J, et al. Impact of hospitalisations for exacerbations of COPD on health-related quality of life. Respir Med. 2009;103(8):1201-1208.80.O'Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J Clin Pract. 2007;61(7):1112-1120.81.Starkie HJ, Briggs AH, Chambers MG, Jones P. Predicting EQ-5D values using the SGRQ. Value Health. 2011;14(2):354-360.82.Steer J, Gibson GJ, Bourke SC. P83?Relations of Different Quality of Life Tools to Subsequent Mortality and Readmission of Patients Surviving Hospitalisation For Acute Exacerbations of COPD: Abstract P83 Table 1. Thorax. 2012;67(Suppl 2):A100.101-A100.83.Kelly J, Crowley, O, Smith, C, Lim, M, Lord, V, Polkey, MI, Hopkinson, NS. Determinants of the COPD assessment test (CAT) score in clinical practice. Am J Respir Crit Care Med. 2011;183(1). ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- c p service clinician s guide veterans affairs
- checklist items and explanations
- issuance of certificate of airworthiness
- contingency plan template
- ap 2 universal application for paad senior gold and
- cat adoption team sherwood cat rescue cat adoption center
- care assessor s manual wa
- consumer outlook the baby boomer generation s
- free enterprise exam
- supplementary material
Related searches
- material and non material cultures
- material and non material elements of culture
- material and non material culture examples
- material and non material culture
- supplementary calculator
- supplementary angle calculator
- how to find the supplementary angles
- two supplementary angles calculator
- complementary and supplementary angle calculator
- how to solve supplementary angles
- complementary supplementary and vertical angles
- non material culture vs material culture